<DOC>
	<DOCNO>NCT03092765</DOCNO>
	<brief_summary>This study placebo-controlled , randomize , double-blind , multicenter , parallel-group comparison study primary biliary cholangitis participant inadequately respond ursodeoxycholic acid .</brief_summary>
	<brief_title>Study E6011 Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding Ursodeoxycholic Acid</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Diagnosed primary biliary cholangitis correspond one follow criterion : Histologically confirm chronic nonsuppurative destructive cholangitis ( CNSDC ) laboratory finding compatible primary biliary cholangitis ( PBC ) Positivity antimitochondrial antibody ( AMAs ) histological finding compatible PBC absence characteristic histological finding CNSDC No histological finding available , positivity AMAs well clinical finding course indicative typical cholestatic PBC Aged ≥20 &lt; 75 year old time inform consent Taking stable dose ursodeoxycholic acid least 6 month ( ≥600 milligram [ mg ] /day ) prior Screening Screening Week 0 alkaline phosphatase ( ALP ) value 1.67 10 time upper limit normal Outpatient Has voluntarily consent , write , participate study , able comply aspect protocol Received follow drug within 12 week start study treatment : Drugs suppose efficacy PBC : azathioprine , colchicine , cyclosporine , methotrexate , mycophenolate mofetil , penicillamine , fibrates , systemic corticosteroid Potentially hepatotoxic drug methyldopa , sodium valproic acid , isoniazide History current condition hepatic decompensation variceal bleeds , encephalopathy ≥ grade 2 poorly control ascites , history liver transplantation History current condition concomitant liver diseases include hepatitis due hepatitis B virus ( HBV ) /hepatitis C virus ( HCV ) infection , primary sclerosing cholangitis , alcoholic liver disease ( include liver cirrhosis ) , autoimmune liver disease require treatment systemic corticosteroid biopsy proven nonalcoholic steatohepatitis ( NASH ) History current clinical condition malignant tumor , lymphoma , leukemia , lymphoproliferative disease , except skin carcinoma ( epithelial carcinoma basal cell carcinoma ) cervix carcinoma completely excise without metastasis recurrence 5 year informed consent Immunodeficiency history human immunodeficiency virus ( HIV ) infection Infection require hospitalization intravenous administration antibiotic disease require administration antivirus drug ( eg , herpes zoster ) within 4 week start study treatment History tuberculosis current complication active tuberculosis Positive tuberculosis test ( QuantiFERON®TB Gold Test TSPOT®.TB Test ) Screening History clinically important vasculitis History severe allergy ( shock anaphylactoid symptom ) Complication uncontrolled disorder acute cardiac infarction , unstable angina , brain infarct , symptomatic intracerebral hemorrhage Evidence clinically significant disease ( eg , cardiac , respiratory , gastrointestinal , renal disease ) could affect participant 's safety interfere study assessment opinion investigator subinvestigator Tested positive follow Screening : HIV , hepatitis B surface ( HBs ) antigen , HBs antibody , hepatitis B core ( HBc ) antibody , HBV deoxyribonucleic acid ( DNA ) , HCV antibody , human Tlymphotropic virus type 1 ( HTLV1 ) antibody , syphilis Demonstrated prolonged QT interval correct use Fridericia 's formula ( QTcF ) interval ( &gt; 450 millisecond [ m ] ) repeat electrocardiogram examination Received immunoglobulin preparation blood product within 24 week start study treatment Received live vaccine within 12 week start study treatment , plan receive Females , may pregnant , breastfeed , wish become pregnant study period , females partner wish use reliable contraceptive measure . Scheduled surgery Week 64 Has treat investigational drug E6011 study Currently enrol another clinical study , include followup Used investigational drug within 28 day ( 5× halflife , whichever long ) inform consent Judged ineligible participate study investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>E6011</keyword>
	<keyword>Ursodeoxycholic acid</keyword>
	<keyword>Japan</keyword>
</DOC>